Mark Fuerst | Authors

Many TNBC Patients Unnecessarily Opt for Mastectomy

June 16, 2017

The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer

June 12, 2017

For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.

Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer

June 04, 2017

The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.